Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | MBI99 | — |
Inappropriate Dose Administered; Inappropriate Dose Administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 32-year-old male patient who received HAV (Havrix 720) (batch number MBI99, expiry date 25-JAN-2027) for prophylaxis. On 10-MAR-2026, the patient received the 1st dose of Havrix 720. On 10-MAR-2026, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Inappropriate Dose Administered) and underdose (Verbatim: Inappropriate Dose Administered). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 10-MAR-2026 A nurse called to get guidance and report that an adult patient was administered with a pediatric dose of HAVRIX. The health care professional wanted to know if there were some recommendations and for how long it was needed to wait before administering the adult dose to the patient. The reporter consented to follow up. The vaccine administration facility was the same as primary reporter.